Telix Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Telix Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.32. The average 1-year stock price forecast is 57.99% higher than the current stock price, while the lowest is $18.00 (+21.95%) and the highest is $32.00 (+116.80%).

Price Target: $23.32 (+57.99%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$18.00	$23.32	$21.45	$32.00
Change	+21.95%	+57.99%	+45.33%	+116.80%

Analyst Ratings

The average analyst rating for Telix Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	9	10	10	8	8	8
Buy	5	4	4	5	6	6
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	14	14	13	14	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Shane Storey Canaccord Genuity	Canaccord Genuity	Buy Maintains $30.00	Buy	Maintains	$30.00	+103.25%	May 25, 2026
David Bailey Morgan Stanley	Morgan Stanley	Buy Maintains $22.40	Buy	Maintains	$22.40	+51.76%	May 24, 2026
John Hester Bell Potter	Bell Potter	Buy Maintains $19.00	Buy	Maintains	$19.00	+28.73%	May 8, 2026
Laura Sutcliffe Citi	Citi	Buy Maintains $32.00	Buy	Maintains	$32.00	+116.80%	Apr 29, 2026
Craig Wong-Pan RBC Capital	RBC Capital	Buy Maintains $18.00	Buy	Maintains	$18.00	+21.95%	Apr 16, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

910.22M

from 803.79M

13.24%

from 803.79M

Revenue Next Year

1.07B

from 910.22M

17.13%

from 910.22M

EPS This Year

0.01

from -0.02

EPS Next Year

0.08

from 0.01

1,026.90%

from 0.01

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Jan 1, 2024	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	5.52M	108.81M	332.98M	516.55M	803.79M	910.22M
Revenue Growth	37.33%	1,870.12%	206.01%	55.13%	55.61%	13.24%
Gross Profit	3.67M	64.52M	203.28M	319.49M	381.85M	503.93M
Gross Margin	66.46%	59.29%	61.05%	61.85%	47.51%	55.36%
Operating Income	-59.08M	-50.37M	34.98M	55.88M	19.29M	37.67M
Net Income	-58.54M	-70.74M	4.21M	33.69M	-7.13M	4.09M
EPS	-	-	-	-	-0.02	0.01
Forward PE	-	-	32.83	87.27	282.12	1,515.40
Free Cash Flow	-27.18M	-20.88M	41.26M	53.71M	-36.67M	7.86M
No. Analysts	-	-	-	-	-	16

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	933.7M
Avg	910.2M
Low	889.9M

Revenue Growth

Revenue Growth	2026	2027	2028
High	16.2%
Avg	13.2%
Low	10.7%

EPS Forecast

EPS	2026	2027	2028
High	0.07
Avg	0.01
Low	-0.04

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-